Literature DB >> 20554971

Modeling the human 8p11-myeloproliferative syndrome in immunodeficient mice.

Helena Agerstam1, Marcus Järås, Anna Andersson, Petra Johnels, Nils Hansen, Carin Lassen, Marianne Rissler, David Gisselsson, Tor Olofsson, Johan Richter, Xiaolong Fan, Mats Ehinger, Thoas Fioretos.   

Abstract

The 8p11 myeloproliferative syndrome (EMS), also referred to as stem cell leukemia/lymphoma, is a chronic myeloproliferative disorder that rapidly progresses into acute leukemia. Molecularly, EMS is characterized by fusion of various partner genes to the FGFR1 gene, resulting in constitutive activation of the tyrosine kinases in FGFR1. To date, no previous study has addressed the functional consequences of ectopic FGFR1 expression in the potentially most relevant cellular context, that of normal primary human hematopoietic cells. Herein, we report that expression of ZMYM2/FGFR1 (previously known as ZNF198/FGFR1) or BCR/FGFR1 in normal human CD34(+) cells from umbilical-cord blood leads to increased cellular proliferation and differentiation toward the erythroid lineage in vitro. In immunodeficient mice, expression of ZMYM2/FGFR1 or BCR/FGFR1 in human cells induces several features of human EMS, including expansion of several myeloid cell lineages and accumulation of blasts in bone marrow. Moreover, bone marrow fibrosis together with increased extramedullary hematopoiesis is observed. This study suggests that FGFR1 fusion oncogenes, by themselves, are capable of initiating an EMS-like disorder, and provides the first humanized model of a myeloproliferative disorder transforming into acute leukemia in mice. The established in vivo EMS model should provide a valuable tool for future studies of this disorder.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20554971     DOI: 10.1182/blood-2009-05-217182

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  12 in total

1.  A model of BCR-FGFR1 driven human AML in immunocompromised mice.

Authors:  John K Cowell; Haiyan Qin; Chang-Sheng Chang; Eiko Kitamura; Mingqiang Ren
Journal:  Br J Haematol       Date:  2015-12-21       Impact factor: 6.998

2.  Constitutive Notch pathway activation in murine ZMYM2-FGFR1-induced T-cell lymphomas associated with atypical myeloproliferative disease.

Authors:  MingQiang Ren; John K Cowell
Journal:  Blood       Date:  2011-04-28       Impact factor: 22.113

3.  Systemic mastocytosis with associated myeloproliferative neoplasm with t(8;19)(p12;q13.1) and abnormality of FGFR1: report of a unique case.

Authors:  Christina B Duckworth; Linsheng Zhang; Shiyong Li
Journal:  Int J Clin Exp Pathol       Date:  2014-01-15

4.  Dysregulated signaling pathways in the development of CNTRL-FGFR1-induced myeloid and lymphoid malignancies associated with FGFR1 in human and mouse models.

Authors:  Mingqiang Ren; Haiyan Qin; Eiko Kitamura; John K Cowell
Journal:  Blood       Date:  2013-06-18       Impact factor: 22.113

5.  Development of ZMYM2-FGFR1 driven AML in human CD34+ cells in immunocompromised mice.

Authors:  Mingqiang Ren; Haiyan Qin; Qing Wu; Natasha M Savage; Tracy I George; John K Cowell
Journal:  Int J Cancer       Date:  2016-05-04       Impact factor: 7.396

6.  Avadomide induces degradation of ZMYM2 fusion oncoproteins in hematologic malignancies.

Authors:  Aline Renneville; Jessica A Gasser; Daniel E Grinshpun; Pierre M Jean Beltran; Namrata D Udeshi; Mary E Matyskiela; Thomas Clayton; Marie McConkey; Kaushik Viswanathan; Alexander Tepper; Andrew A Guirguis; Rob S Sellar; Sophie Cotteret; Christophe Marzac; Véronique Saada; Stéphane De Botton; Jean-Jacques Kiladjian; Jean-Michel Cayuela; Mark Rolfe; Philip P Chamberlain; Steven A Carr; Benjamin L Ebert
Journal:  Blood Cancer Discov       Date:  2021-03-10

7.  SOCS2 is dispensable for BCR/ABL1-induced chronic myeloid leukemia-like disease and for normal hematopoietic stem cell function.

Authors:  N Hansen; H Ågerstam; M Wahlestedt; N Landberg; M Askmyr; M Ehinger; M Rissler; H Lilljebjörn; P Johnels; J Ishiko; J V Melo; W S Alexander; D Bryder; M Järås; T Fioretos
Journal:  Leukemia       Date:  2012-06-22       Impact factor: 11.528

8.  Modeling chronic myeloid leukemia in immunodeficient mice reveals expansion of aberrant mast cells and accumulation of pre-B cells.

Authors:  M Askmyr; H Ågerstam; H Lilljebjörn; N Hansen; C Karlsson; S von Palffy; N Landberg; C Högberg; C Lassen; M Rissler; J Richter; M Ehinger; M Järås; T Fioretos
Journal:  Blood Cancer J       Date:  2014-12-12       Impact factor: 11.037

9.  Screening of drugs to treat 8p11 myeloproliferative syndrome using patient-derived induced pluripotent stem cells with fusion gene CEP110-FGFR1.

Authors:  Shohei Yamamoto; Makoto Otsu; Emiko Matsuzaka; Chieko Konishi; Haruna Takagi; Sachiyo Hanada; Shinji Mochizuki; Hiromitsu Nakauchi; Kohzoh Imai; Kohichiro Tsuji; Yasuhiro Ebihara
Journal:  PLoS One       Date:  2015-03-24       Impact factor: 3.240

10.  Transgenic expression of human cytokines in immunodeficient mice does not facilitate myeloid expansion of BCR-ABL1 transduced human cord blood cells.

Authors:  Maria Askmyr; Sofia von Palffy; Nils Hansen; Niklas Landberg; Carl Högberg; Marianne Rissler; Helena Ågerstam; Thoas Fioretos
Journal:  PLoS One       Date:  2017-10-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.